Unknown to the family, the consultants had been working with University College London on a cutting-edge new genetic treatment. It works by tweaking the DNA of donor immune cells so they would only target leukaemia cells and would not be rejected by the body. It was hoped that a transfusion of the cells would clear Layla’s body of any remaining leukaemia so that she could have a bone marrow transplant to reboot her immune system.